Establishes requirements for State entities to enter into bulk purchasing arrangements for pharmaceutical products.

This bill requires New Jersey's Director of the Division of Purchase and Property to review state pharmaceutical purchasing and create an annual prioritization list for bulk buying. The list focuses on the 25 highest-cost drugs/devices used by state programs, considering price, availability of similar alternatives, and must explain if any top-cost item is excluded. The director will coordinate with health agencies to implement bulk purchasing for priority items and develop outreach to help counties, local governments, and private buyers (like small businesses) access these savings. It mandates annual reports to the Governor and Legislature on cost impacts, drug availability, and benefits for participating groups.